On November 10, TG Therapeutics rose 5.41% in Regular Trading, with shares trading at $62.78 and turnover reaching $207 million.
The move followed its latest quarterly results, which showed third-quarter revenue of $259.9 million, above the $245.5 million market expectation, alongside an increase in total global revenue guidance to about $1.0 billion from $950 million previously.
Profit was mixed: diluted EPS came in at $0.35, versus $2.43 a year earlier and slightly below some forecasts, but revenue increased from $161.7 million a year ago. The market reaction suggests investors focused more on stronger top-line growth and the higher full-year outlook, indicating continued commercialization momentum for the company’s core multiple sclerosis product portfolio.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments